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Hepatitis C virus (HCV) infection is probably the most common chronic viral infection and affects an estimated 180 million people
worldwide, accounting for 3% of the global population. Although the liver is considered to be the primary target, extrahepatic
manifestations are well recognized among patients with chronic HCV infection. Epidemiological studies have clearly demonstrated
a correlation between chronic HCV infection and occurrence of B-cell non-Hodgkin’s lymphomas (B-NHL). The clinical evidence
that antiviral therapy has a significant role in the treatment at least of some HCV-associated lymphoproliferative disorders,
especially indolent B-NHL, further supports the existence of an etiopathogenetic link. However, the mechanisms exploited by HCV
to induce B-cell lymphoproliferation have so far not completely clarified. It is conceivable that different biological mechanisms,
namely, chronic antigen stimulation, high-affinity interaction between HCV-E2 protein and its cellular receptors, direct HCV
infection of B-cells, and “hit and run” transforming events, may be combined themselves and cooperate in a multifactorial model
of HCV-associated lymphomagenesis.
1. Introduction
Hepatitis C virus (HCV) is an enveloped positive, single-
stranded RNA virus, belonging to the Flaviviridae fam-
ily [1]. During its replicative cycle it goes through a
negative-stranded RNA, but not DNA, intermediate, so
that integration of HCV nucleic acid sequences into the
host genome seems unlikely. The HCV genome encodes a
single polyprotein precursor of approximately 3000 amino
acids, which is proteolytically processed by viral and cellular
proteases to produce structural (nucleocapsid, E1, and E2)
and nonstructural (NS) proteins (NS2, NS3, NS4A, NS4B,
NS5A, and NS5B). The HCV envelope proteins consist of
two heavily glycosylated proteins, E1 and E2, which act as
the ligands for cellular receptors [1, 2].
Human CD81 is the first identified necessary receptor
for HCV cell entry, which can directly bind with HCV E2
protein [3, 4]. CD81 is a widely distributed cell-surface
tetraspanin that participates in different molecular com-
plexes on various cell types, including hepatocytes, B-lymp-
hocytes, T-lymphocytes, and natural killer cells. It has been
proposed that HCV exploits CD81 not only to invade
hepatocytes but also to modulate the host immune responses
[5].
Infection with HCV affects an estimated 180 million
people, accounting for 3% of the global population [6,
7]. HCV is a well-recognized etiologic agent of chronic
hepatitis. Although the natural history of HCV infection
is highly variable, an estimated 15% to 30% of patients
in whom chronic infection develops have progression to
cirrhosis over the ensuing three decades, and these latter
patients warrant surveillance for complications, including
hepatocellular carcinoma (HCC), which develops in 1%–3%
of such patients per year [6, 7]. Indeed, the risk of HCC in
the HCV-infected population is 23–35 times higher than in
noninfected healthy individuals [8, 9].
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Although the liver is considered to be the primary
target of HCV infection, extrahepatic manifestations, such as
mixed cryoglobulinemia (MC), which is a systemic immune
complex-mediated disorder characterized by B-cell prolifer-
ation that may evolve into overt B-cell non-Hodgkin’s lym-
phoma (B-NHL) in about 10%–20% of patients several years
after diagnosis, are often recognized among patients with
chronic HCV infection [10–12]. Moreover, epidemiological
evidences strongly suggest a close link between chronic HCV
infection and de novo B-NHL, not complicating the course
of MC [13–16]. The possible pathogenetic mechanisms of
HCV-induced B-cell lymphomagenesis are reviewed.
2. Epidemiologic Association of
HCV and B-NHL
Evans and Mueller proposed that either epidemiologic or
virologic guidelines need to be fulfilled to support an
etiologic role for a virus in a given human cancer [17].
Suggested epidemiologic guidelines included the following:
(a) the geographic distribution of viral infection should
coincide with that of the tumor; (b) the presence of viral
markers should be higher in case subjects than in matched
control subjects; (c) viral markers should precede the tumor,
with a higher incidence of tumors in persons with the marker
than in those without; (d) prevention of viral infection
should decrease tumor incidence [17]. Suggested virologic
guidelines included the following: (a) the virus should be
able to transform human cells in vitro; (b) the viral genome
should be demonstrated in tumor cells and not in normal
cells; (c) the virus should be able to induce the tumor in an
experimental animal [17].
As far as the association between HCV infection and
occurrence of B-NHL is concerned, most of the epidemi-
ologic guidelines for causality from Evans and Mueller are
met. HCV is associated with certain B-NHL types, especially
in geographic areas with HCV endemicity, like Italy, Japan,
and Egypt, where prevalence rates range from 20% to 40%
[14, 15, 18–21], whereas in nonendemic areas, as Northern
Europe, North America and United Kingdom, the prevalence
of HCV infection in B-NHL is far less than 5% [22–24].
The possibility is raised that in these latter geographic areas
where HCV prevalence among subjects not affected with B-
NHL is low, the spread of the virus may be recent, thus not
allowing the full consequences on B-NHL development to
be observed. Moreover, studies from areas with low HCV
prevalence may not have included sufficient numbers of
patients to detect a significant association between HCV
and B-NHL [16]. Taken together, the epidemiologic analyses
demonstrated that the prevalence of HCV infection in
patients with B-NHL is approximately 15% [25]. The preva-
lence of anti-HCV antibodies and/or HCV RNA sequences is
significantly higher in patients with B-NHL than in patients
with other lymphoid malignancies or in age matched healthy
subjects. Furthermore, HCV infection often precedes by
years the occurrence of lymphomas [26]. In a recent meta-
analysis focusing on 15 studies, the pooled relative risk (RR)
of all B-NHL among HCV-positive persons was found to be
2.5 (95% confidence interval (CI), 2.1–3.1) in case-control
studies and 2.0 (95% CI, 1.8–2.2) in cohort studies [27].
Another meta-analysis reviewed data from 23 studies (4,049
NHL patients and 1,813,480 controls) and found a stronger
association (odds ratio 5.70) [28]. It should be noted that RR,
although moderate (2-3 on average) in comparison to HCV
and HCC association, were similarly increased for all major
B-NHL subtypes and primary sites of presentation [16, 29].
Only slightly higher RR for extranodal compared with nodal
B-NHL were reported for HCV-positive patients, but this
difference was largely due to the early studies. Moreover,
extensive studies did not demonstrate clear differences on
the association between HCV and major histologic B-
NHL subtypes, either indolent, namely, follicular, marginal
zone (MZL), lymphoplasmacytic, and chronic lymphocytic
leukemia/small lymphocytic lymphoma, or aggressive diffuse
large B-cell (DLBCL) and Burkitt lymphoma [16, 29, 30].
In fact, earliest studies suggesting a stronger association
of HCV with certain subtypes, such as lymphoplasma-
cytic/Waldenstrom lymphomas, were performed mainly in
HCV-infected subjects with MC, a subset of patients in
which these lymphoma subtypes have been reported to be
highly prevalent [16, 29]. Conversely, one of the largest case-
control studies to date found a higher OR (3.5 versus 2.3)
for aggressive versus indolent lymphomas, respectively, and
suggested that previous data may have also been influenced
by the relatively poorer prognosis associated with aggressive
lymphomas [14]. Patients with HCV-related DLBCL may
have more aggressive clinical features at presentation in
comparison to HCV-negative patients [31, 32].
The possible association between specific viral geno-
types and malignant lymphoproliferative disorders remains
a controversial issue. There are at least six major HCV
genotypes whose prevalence varies geographically. Genotype
1 accounts for the majority of infections in North America,
South America, and Europe [7]. Various clinical studies
failed to demonstrate a link between specific viral genotypes
and B-NHL, but it should also be noted that this issue
was not specifically addressed in several other series. Luppi
et al. documented an unexpectedly lower prevalence of
HCV genotype 1b/II in patients with B-NHL. Conversely,
the prevalence of genotypes 2a/III and 2b/IV was higher
in patients with B-NHL than in either hemodialysis or
chronic liver disease patients, thus suggesting that different
HCV variants may show greater lymphotropism [33]. Recent
epidemiologic evidence from a multicenter retrospective
study also suggested that genotype 2 may be more prevalent
and carcinogenic in lymphoma patients [34]. In details,
HCV-positive patients were classified as cancer patients (129
patients, including 53 hematologic malignancies and 76
solid tumors), immunocompetent (333 subjects) and HCV-
HIV coinfected (102 patients). Genotype 1 predominated
(84%) in immunocompetent as compared to patients with
HCC (74%, P = .08) or lymphoma (59%, P = .001).
By contrast, genotype 2 was more prevalent in patients
with lymphoma (24%), compared to immunocompetent
(8%, P = .003), yielding a 3-fold increase in cancer
risk among HCV-infected patients than other genotypes
[34]. Interestingly, Pellicelli et al. [19] observed that DLBCL
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patients had a higher prevalence of genotype 1 and a shorter
duration of HCV infection, as compared to patients with
indolent, low-grade B-NHL, who showed a higher prevalence
of genotype 2 and longer duration of HCV infection. Because
HCV genotype 2 is associated with a longer duration of
viral infection, it has been speculated that over time it
may induce a persistent chronic immunostimulation of B-
cells. On the contrary, direct lymphocyte transformation
could be hypothesized for HCV genotype 1 in aggressive
lymphomas, on the basis of the shorter duration of viral
exposure [19]. Future perspective studies enrolling a large
number of patients are warranted to further investigate the
different distribution and carcinogenic potential of different
HCV genotypes.
The regression of HCV-related B-NHL following antivi-
ral therapy probably represents the strongest argument in
favor of an etiologic link between HCV infection and certain
human lymphomas [16, 26]. Several clinical trials showed
that antiviral therapy, mostly based on peg-interferon and
ribavirin, resulted in either complete or partial remissions
of lymphoma in HCV-positive but not HCV-negative B-
NHL patients [29, 35–37]. A systematic review has shown
that complete responses were achieved in 75% of the
HCV-positive cases [38]. Lymphoma regression was usu-
ally positively correlated with viral load reduction [29].
These trials have been conducted in asymptomatic indolent
lymphomas during a phase in which no other therapeutic
intervention was administered. For aggressive lymphoma or
symptomatic indolent lymphoma, HCV eradication alone
is not an option. These patients require systemic therapy
with rituximab and chemotherapy-based regimens as first
treatment. Nevertheless, antiviral therapy to eradicate HCV
may be an option after successful lymphoma therapy.
Whether HCV eradication after-chemoimmunotherapy may
impact future survival outcome remains uncertain [29].
Regarding this topic, La Mura et al. retrospectively analyzed
343 patients affected with NHL [39]. Twenty-five of the 69
HCV-positive subjects received antiviral therapy (interferon
and ribavirin) following antineoplastic treatment, in order
to eradicate HCV infection. Overall survival (OS) was
slightly better in HCV-infected NHL patients treated with
antiviral therapy compared with untreated, even if without
statistically significance. Conversely, disease-free survival
(DFS) was significantly improved in treated versus untreated
patients. A sustained virologic response was obtained in
8/25 (32%) HCV-positive NHL patients who underwent
antiviral treatment. None of the patients who eradicated
HCV infection had a lymphoma relapse at followup, whereas
5/17 of those who did not respond to antiviral therapy expe-
rienced relapses. At multivariate analysis, the independent
factors related to a better DFS in this series were antiviral
therapy and indolent histology at the onset of lymphoma
[39]. Antiviral treatment may be a strategy to reinforce the
results of successful chemoimmunotherapy regimens, but
future prospective studies are needed to further investigate
this clinical issue. Of interest, a recent study has shown that
HCV-infected patients who had received interferon therapy
and had experienced a sustained virologic response had a
hazard ratio of lymphomagenesis that was significantly lower
than patients who had not received antiviral treatment [40].
These data suggest that antiviral treatment may also be
efficacious in preventing lymphomagenesis in HCV-infected
patients. Moreover, it should be of interest to investigate
the impact of newer directly acting antiviral agents, such
as protease inhibitors telaprevir and boceprevir [11, 41–43],
on the future prevalence and clinical outcome of B-NHL
in patients with chronic HCV infection. While reactivation
risk of hepatitis B virus (HBV) after chemoimmunotherapy
is well recognized and prophylactic antiviral therapy to
suppress HBV-DNA is widely recommended, the issue of
HCV reactivation in lymphoma patients undergoing anti-
neoplastic treatments is lesser understood [29, 44]. However,
a significant proportion of patients with HCV-positive NHL,
when treated with conventional chemoimmunotherapy, may
develop liver toxicity due to either direct cytotoxicity or
increased drug toxicity from suboptimal drug metabolism
[29, 45]. The addition of rituximab to chemotherapy does
not seem to impact significantly on liver toxicity [45]. HCV-
RNA levels appear to increase during chemoimmunotherapy
as a result of viral reactivation, but HCV-RNA levels
subsequently decrease at 6 months posttreatment, often
without major clinical consequences to most patients [44].
Nevertheless, it should also be noted that massive liver
necrosis may occur in HCV-positive lymphoma patients on
withdrawal of chemotherapy or reduction of corticosteroids,
suggesting an immune-mediated mechanism of hepatic
damage [44, 46]. Without initial liver dysfunction, HCV-
positive patients with NHL could experience a similar
outcome compared with their HCV-negative counterparts,
when treated with conventional chemoimmunotherapy [44,
47]. A protective role of antiviral prophylaxis to suppress
HCV replication during antineoplastic treatments has not
yet been defined [29, 44]. Prospective studies and longer
followups are necessary to ascertain whether HCV-positive
B-NHL patients have inferior outcome or whether there
would be long term consequences of chemoimmunotherapy
on the progression of liver disease [47]. Patients with HCV
infection and lymphoma are recommended to be carefully
monitored for hepatotoxicity and HCV-RNA levels. Further-
more, hematologists and hepatologists should work closely
together in order to optimize the management of HCV
infection throughout lymphoma treatment and improve
clinical outcome [29].
3. Mechanisms of HCV-Induced
Lymphoproliferation
The biological rational for investigating a causal association
between HCV infection and the occurrence of B-NHL is
based on epidemiological and clinical observations. Never-
theless, limited information are so far available about the bio-
logical mechanisms of HCV-induced lymphoproliferation.
Evidences from experimental studies suggest that several
different mechanisms may be involved in HCV-mediated B-
cell transformation [16, 29, 48].
Similarly to the association of Helicobacter pylori infec-
tion and gastric MALT lymphoma, the concept of chronic
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Figure 1: (A–D) The different oncogenetic mechanisms are not mutually exclusive, but they may be integrated and cooperate in a
multifactorial pathogenetic model of HCV-associated B-cell lymphoproliferation.
antigen stimulation leading to a monoclonal malignant
proliferation may also be applied to HCV (Figure 1(A))
[49, 50]. Interestingly, HCV-associated B-NHL generally
originate from germinal center (GC) or post-GC B-cells,
suggesting that lymphomagenesis occurs when B-cells expe-
rience somatic hypermutation and proliferate in response
to an antigen [51, 52]. Further evidence comes from the
antibody response and immunoglobulin variable (Ig VH)
gene usage in patients with chronic HCV infection and
HCV-associated B-NHL. In three out of five HCV-positive
nodal MZLs, Marasca et al. revealed the usage of the VH1-
69 gene with similar CDR3, indicating a highly biased and
nonrandom use of the VH segments in this subtype of
tumors [53]. These data indicated the role of a common
antigenic epitope involved in the selection and in the
expansion of the B-cell clone at the origin of neoplastic
cells. The VH1-69 immunoglobulin segment is expressed in
the restricted repertoire of fetal liver B lymphocytes and is
thought to be involved in natural immunity. A productive
VH1-69 rearrangement is present in 1.6% of normal B
lymphocytes in adults. VH1-69 is rearranged in 10% to
20% of B-cell chronic lymphocytic leukemia and a VH1-69
monoclonal rearrangement is also present in the majority
of patients with type II MC, a typical HCV-related disorder
[53]. Further experimental sequencing of clonal Ig variable
regions from both MC and HCV-associated B-NHL patients
documented restricted IgV gene repertoire, with expression
of VH and VL genes (VH1-69 and Vκ3-A27), suggesting
exposure and response to a common antigen [54–56]. Of
note, HCV-E2 protein is the primary target of antibody
responses against HCV [57]. Quinn et al. obtained the
cloning of the B-cell receptor from one HCV-positive DLBCL
and its expression as a soluble immunoglobulin [58]. The
immunoglobulin rescued was shown to bind the HCV-E2
glycoprotein in a manner identical to a bona fide human
anti-E2 antibody, suggesting that some HCV-associated B-
NHL may originate from B-cells that were initially activated
by HCV-E2 protein [58]. Similarly, in a reported case of
an HCV-associated plasma cell leukemia, immunoblotting
showed that the monoclonal IgG-kappa detected in the
serum was directed against a viral protein, namely, the
HCV core protein [59]. These and other studies suggest an
indirect, antigen-driven lymphomagenetic role of HCV, with
HCV-E2 protein recognized as one of the most important
antigens involved in chronic B-lymphocyte stimulation [16,
26, 29].
A second mechanism, potentially involved in HCV-
associated lymphomagenesis, derives from the high-affinity
binding between HCV-E2 and one of its receptors, the
tetraspanin CD81, expressed on B-cells (Figure 1(B)) [16].
CD81 is known to form B-cell costimulatory complex with
CD19, CD21, and interferon-inducible Leu-13 (CD225)
proteins. This complex reduces the threshold for B-cell
activation via the B-cell receptor by bridging antigen specific
recognition and CD21-mediated complement recognition
[60, 61]. It was reported that engagement of CD81 on human
B-cells by a combination of HCV E2 protein and anti-CD81
mAb leads to the proliferation of naive B-cells, and E2-
CD81 interaction induces protein tyrosine phosphorylation
and hypermutation of the immunoglobulin genes in B-
cell lines [62]. In addition to direct effects on B-cells,
engagement of CD81 on T-cells lowered the threshold for
interleukin-2 production, resulting in strongly increased T-
cell proliferation. This could lead to T-cell activation in
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response to suboptimal stimuli and bystander activation
of B-cells [63]. Taken together, these results suggest that
CD81 engagement on B- and T-cells may lead to direct
or indirect activation [16]. Chronic B-cell proliferation, in
response to antigenic stimulation or polyclonal activation,
may predispose to genetic lesions such as translocation
and/or overexpression of the antiapoptotic protein Bcl-2
[64]. In a recent study, human Burkitt’s lymphoma cell line
(Raji cells) and primary human B lymphocytes (PHB) were
treated with HCV-E2 protein and HCV particles produced
by cell culture (HCVcc) [65]. The results showed that both
E2 and HCVcc triggered phosphorylation of IkBα, with
subsequent increased expression of NF-kB and NF-kB target
genes, such as antiapoptotic Bcl-2 family proteins (Bcl-2
and Bcl-xL). Either Raji cells or PHB cells were protected
from FAS-mediated death. In addition, both E2 protein and
HCVcc increased the expression of costimulatory molecules
CD80, CD86, and CD81 itself, and decreased the expression
of complement receptor CD21. The effects were dependent
on E2-CD81 interaction on the cell surface, since CD81-
silenced Raji cells did not respond to both treatments.
Moreover, an E2 mutant that loses the CD81 binding activity
could not trigger the responses of both Raji cells and PHB
cells. Of note, the effects were not associated with HCV
replication in cells [65]. Hence, E2-CD81 engagement plays a
role in activating B-cells, protecting B-cells from activation-
induced cell death, and regulating immunological function.
These latter mechanisms may contribute to the pathogenesis
of HCV-associated B-cell lymphoproliferative disorders [65].
Moreover, the interaction between HCV-E2 and CD81 on B-
cells has been shown to stimulate the enhanced expression of
activation-induced cytidine deaminase (AID) and to induce
double-strand DNA breaks in the IgVH gene locus, thereby
contributing to a mutator phenotype that increases the risk
of B-cell malignant transformation [66].
Another oncogenetic mechanism that has been proposed
is the direct infection of B-cells by HCV (Figure 1(C))
[16, 29, 67]. In the early 1990s, the presence of HCV-
RNA was demonstrated by PCR not only in serum/plasma
and liver tissues but also in peripheral blood mononuclear
cells (PBMCs), especially in B-cells, of patients infected
with HCV [68–71]. Nevertheless, although HCV has been
detected in lymphocytes from HCV infected patients and
patients with MC, only in a minority of cases RNA-negative
strands, the HCV replicative intermediates suggestive of
viral replication, were also detected in the cells [72–74].
Detection of negative-strands HCV-RNA in PBMCs by
polymerase chain reaction, may also be due to either
contamination or passive absorption of circulating HCV,
thus potentially leading to false positive results [75, 76].
Marukian et al. showed that culture-grown HCV replicated
in hepatoma cells, but no HCV replication was detected
in B- or T-cells, monocytes, macrophages, or dendritic
cells from healthy donors [77]. Furthermore, Stamataki et
al. have provided experimental evidence that HCV might
infect B-cells, but B-cells were not able to support active
viral replication [78]. Overall, these results should indicate
that PBMC may not be permissive to HCV replication
[16].
However, it has been reported that HCV may infect
and replicate only in a relatively rare subset of B-cells, such
as CD5+ B-cells. These cells have been shown to express
high levels of CD81 and to expand in HCV-infected liver
[79]. Alternatively, B-cells may need another event, such
as coinfection with another virus, namely, Epstein-Barr
virus (EBV), to become permissive for HCV infection and
replication [16, 80]. Neither HCV-RNA nor viral proteins
have generally been detected in lymphomatous cells in vivo,
with a few exceptions, for example a primary DLBCL of
the liver, found to harbor viral nucleic acids by in situ
hybridization and a mantle cell lymphoma case, from which
a lymphoma cell line could be established in vitro [26, 81,
82]. Moreover, Sung et al. established a B-cell line (SB)
from an HCV-infected B-NHL, whose virions could infect
primary human hepatocytes, PBMCs, and an established B-
cell line (Raji cells) in vitro [83]. Further studies provided
evidence that HCV replicates in various hematopoietic cell
types, including peripheral dendritic cells, monocytes, and
macrophages [84–86]. Overall, despite the evidence that
HCV can infect B-cells, the results about its capacity to
replicate in B-cells and other blood mononuclear cells and
to induce direct malignant lymphoproliferation still appear
highly conflicting [16, 29].
A Japanese group recently established HCV trans-
genic mice that expressed the full HCV genome in B-
cells (RzCD19Cre mice) [87]. Interestingly, RzCD19Cre
mice with substantially elevated serum-soluble interleukin-
2 receptor α-subunit (sIL-2Rα) levels developed B-NHL.
Another mouse model of lymphoproliferative disorder was
established by persistent expression of HCV structural
proteins through disruption of interferon regulatory factor-1
(irf-1 −/−/CN2 mice). Irf-1 −/−/CN2 mice showed extremely
high incidences of lymphomas and lymphoproliferative
disorders. Moreover, these mice showed increased levels
of interleukin (IL)-2 and IL-10, as well as increased Bcl-
2 expression, which promoted oncogenic transformation
of lymphocytes. In this mouse model, the overexpres-
sion of apoptosis-related proteins and/or aberrant cytokine
production were the primary events involved in inducing
lymphoproliferation [87].
A recent study found that peripheral blood B-cells
from patients with chronic HCV infection were infected
and also had enhanced gene expression associated with B-
NHL development when compared to healthy controls [88].
Furthermore, HCV has been found to induce high mutation
frequency of cellular genes (immunoglobulin heavy chain,
Bcl-6, p53 and beta-catenin genes), in B-cell lines and
PBMCs in vitro, by inducing double strand breaks and
by activating error-prone-polymerases and AID [89]. These
mutations of cellular genes are amplified in HCV-associated
B-NHL in vivo, suggesting that HCV-induced mutations
in proto-oncogenes and tumor suppressor genes may lead
to oncogenetic transformation of the infected B-cells. The
so-called mutator phenotype induced by HCV acute and
chronic infection in B-cells may be considered a “hit and
run” mechanism of cell transformation (Figure 1(D)) [89].
It has been proposed that HCV uses B-cells as reservoirs
for persistent infection, which could result in the enhanced
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expression of lymphomagenesis-related genes, particularly
AID, which is thought to be crucial for the initiation and
progression of B-NHL [67]. Other studies suggested that
the evolution from lymphoproliferation to malignancy may
require a second transforming event such as the antiapop-
totic Bcl-2 rearrangement. The t(14;18) translocation is
indeed significantly associated with chronic HCV infection
and particularly with MC [90, 91]. Although the role of virus
penetration and replication in B-cells has still to be fully
clarified, several evidences suggest that the presence of HCV
virus or HCV proteins in these cells represents an oncogenic
stimulus [16, 29].
4. Conclusion
Epidemiological studies have clearly demonstrated a cor-
relation between chronic HCV infection and occurrence
of B-NHL. The clinical evidence that antiviral therapy
has a significant role in the treatment and prevention of
some HCV-associated lymphoproliferative disorders, espe-
cially indolent B-NHL, further supports the existence of an
etiopathogenetic link. The mechanisms exploited by HCV
to induce B-cell lymphoproliferation differ from the clas-
sical mechanisms of herpesviral-induced lymphomagenesis,
which require the maintenance of either EBV or human
herpesvirus-8 genomes in the transformed B-cells as clonal
episomes, together with the expression of an array of latent
and, to a lesser extent, of lytic proteins [92]. It is conceivable
that the different mechanisms proposed, namely, chronic
antigen stimulation, high-affinity interaction between HCV-
E2 protein, and its cellular receptors, direct HCV infection
of B-cells and “hit and run” transforming events, are not
mutually exclusive, but they may be combined themselves in
a multifactorial model of HCV-associated lymphomagenesis
(Figure 1(A–D)) [16, 26, 29, 67].
Conflict of Interests
The authors indicated that there are no potential conflicts of
interests.
Acknowledgments
This work was supported by Associazione Italiana per
la Ricerca sul Cancro, Milan, Italy GRANT No. (AIRC
IG10621-2010).
References
[1] B. Clarke, “Molecular virology of hepatitis C virus,” Journal of
General Virology, vol. 78, no. 10, pp. 2397–2410, 1997.
[2] A. O. De Beeck, L. Cocquerel, and J. Dubuisson, “Biogenesis of
Hepatitis C virus envelope glycoproteins,” Journal of General
Virology, vol. 82, no. 11, pp. 2589–2595, 2001.
[3] P. Pileri, Y. Uematsu, S. Campagnoli et al., “Binding of
hepatitis C virus to CD81,” Science, vol. 282, no. 5390, pp. 938–
941, 1998.
[4] B. D. Lindenbach, M. J. Evans, A. J. Syder et al., “Virology:
complete replication of hepatitis C virus in cell culture,”
Science, vol. 309, no. 5734, pp. 623–626, 2005.
[5] S. Levy, S. C. Todd, and H. T. Maecker, “CD81 (TAPA-1): a
molecule involved in signal transduction and cell adhesion in
the immune system,” Annual Review of Immunology, vol. 16,
pp. 89–109, 1998.
[6] M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff,
“Diagnosis, management, and treatment of hepatitis C: an
update,” Hepatology, vol. 49, no. 4, pp. 1335–1374, 2009.
[7] H. R. Rosen, “Chronic hepatitis C infection,” New England
Journal of Medicine, vol. 364, no. 25, pp. 2429–2438, 2011.
[8] J. Amin, G. J. Dore, D. L. O’Connell et al., “Cancer incidence
in people with hepatitis B or C infection: a large community-
based linkage study,” Journal of Hepatology, vol. 45, no. 2, pp.
197–203, 2006.
[9] R. Strauss, A. Törner, A. S. Duberg, R. Hultcrantz, and K.
Ekdahl, “Hepatocellular carcinoma and other primary liver
cancers in hepatitis C patients in Sweden–a low endemic
country,” Journal of Viral Hepatitis, vol. 15, no. 7, pp. 531–537,
2008.
[10] G. Pozzato, C. Mazzaro, M. Crovatto et al., “Low-grade
malignant lymphoma, hepatitis C virus infection, and mixed
cryoglobulinemia,” Blood, vol. 84, no. 9, pp. 3047–3053, 1994.
[11] V. Agnello, R. T. Chung, and L. M. Kaplan, “A role for hepatitis
C virus infection in Type II cryoglobulinemia,” New England
Journal of Medicine, vol. 327, no. 21, pp. 1490–1495, 1992.
[12] C. Ferri, A. L. Zignego, and S. A. Pileri, “Cryoglobulins,”
Journal of Clinical Pathology, vol. 55, no. 1, pp. 4–13, 2002.
[13] C. Ferri, F. Caracciolo, A. L. Zignego et al., “Hepatitis C virus
infection in patients with non-Hodgkin’s lymphoma,” British
Journal of Haematology, vol. 88, no. 2, pp. 392–394, 1994.
[14] A. Mele, A. Pulsoni, E. Bianco et al., “Hepatitis C virus and
B-cell non-Hodgkin lymphomas: an Italian multicenter case-
control study,” Blood, vol. 102, no. 3, pp. 996–999, 2003.
[15] M. Luppi, G. Longo, M. G. Ferrari et al., “Clinico-pathological
characterization of hepatitis C virus-related B- cell non-
Hodgkin’s lymphomas without symptomatic cryoglobuline-
mia,” Annals of Oncology, vol. 9, no. 5, pp. 495–498, 1998.
[16] F. Marcucci and A. Mele, “Hepatitis viruses and non-Hodgkin
lymphoma: epidemiology, mechanisms of tumorigenesis, and
therapeutic opportunities,” Blood, vol. 117, no. 6, pp. 1792–
1798, 2011.
[17] A. S. Evans and N. E. Mueller, “Viruses and cancer. Causal
associations,” Annals of Epidemiology, vol. 1, no. 1, pp. 71–92,
1990.
[18] P. Cocco, G. Piras, M. Monne et al., “Risk of malignant
lymphoma following viral hepatitis infection,” International
Journal of Hematology, vol. 87, no. 5, pp. 474–483, 2008.
[19] A. M. Pellicelli, M. Marignani, and V. Zoli, “Hepatitis C virus-
related subtypes in non Hodgkin’s lymphoma,” World Journal
of Hepatology, vol. 3, pp. 278–284, 2011.
[20] F. Mizorogi, J. Hiramoto, A. Nozato et al., “Hepatitis C virus
infection in patients with B-cell non-Hodgkin’s lymphoma,”
Internal Medicine, vol. 39, no. 2, pp. 112–117, 2000.
[21] L. Goldman, S. Ezzat, N. Mokhtar et al., “Viral and non-
viral risk factors for non-Hodgkin’s lymphoma in Egypt:
heterogeneity by histological and immunological subtypes,”
Cancer Causes and Control, vol. 20, no. 6, pp. 981–987, 2009.
[22] P. Hausfater, P. Cacoub, Y. Sterkers et al., “Hepatitis C virus
infection and lymphoproliferative diseases: prospective study
on 1,576 patients in France,” American Journal of Hematology,
vol. 67, no. 3, pp. 168–171, 2001.
Clinical and Developmental Immunology 7
[23] J. D. Collier, B. Zanke, M. Moore et al., “No association
between hepatitis C and B-cell lymphoma,” Hepatology, vol.
29, no. 4, pp. 1259–1261, 1999.
[24] T. Sy and M. M. Jamal, “Epidemiology of hepatitis C virus
(HCV) infection,” International Journal of Medical Sciences,
vol. 3, no. 2, pp. 41–46, 2006.
[25] J. P. Gisbert, L. Garcı́a-Buey, M. J. Pajares, and R. Moreno-
Otero, “Prevalence of hepatitis C virus infection in B-cell non-
Hodgkin’s lymphoma: systematic, review and meta-analysis,”
Gastroenterology, vol. 125, no. 6, pp. 1723–1732, 2003.
[26] M. Luppi, P. Barozzi, L. Potenza, G. Riva, M. Morselli, and G.
Torelli, “Is it now the time to update treatment protocols for
lymphomas with new anti-virus systems?” Leukemia, vol. 18,
no. 10, pp. 1572–1575, 2004.
[27] L. Dal Maso and S. Franceschi, “Hepatitis C virus and risk of
lymphoma and other lymphoid neoplasms: a meta-analysis of
epidemiologic studies,” Cancer Epidemiology Biomarkers and
Prevention, vol. 15, no. 11, pp. 2078–2085, 2006.
[28] K. Matsuo, A. Kusano, A. Sugumar, S. Nakamura, K. Tajima,
and N. E. Mueller, “Effect of hepatitis C virus infection on
the risk of non-Hodgkin’s lymphoma: a meta-analysis of
epidemiological studies,” Cancer Science, vol. 95, no. 9, pp.
745–752, 2004.
[29] S. K. Hartridge-Lambert, E. M. Stein, A. J. Markowitz, and
C. S. Portlock, “Hepatitis C and non-Hodgkin lymphoma: the
clinical perspective,” Hepatology, vol. 55, pp. 634–641, 2012.
[30] L. A. Martyak, M. Yeganeh, and S. Saab, “Hepatitis C and
lymphoproliferative disorders: from mixed cryoglobulinemia
to non-Hodgkin’s lymphoma,” Clinical Gastroenterology and
Hepatology, vol. 7, no. 8, pp. 900–905, 2009.
[31] C. Besson, D. Cantoni, E. Lepage et al., “Characteristics and
outcome of diffuse large B-cell lymphoma in hepatitis C virus-
positive patients in LNH 93 and LNH 98 groupe d’etude
des lymphomes de l’adulte programs,” Journal of Clinical
Oncology, vol. 24, no. 6, pp. 953–960, 2006.
[32] D. Ennishi, Y. Maeda, N. Niitsu et al., “Hepatic toxicity and
prognosis in hepatitis C virus-infected patients with diffuse
large B-cell lymphoma treated with rituximab-containing
chemotherapy regimens: a Japanese multicenter analysis,”
Blood, vol. 116, no. 24, pp. 5119–5125, 2010.
[33] M. Luppi, M. G. Ferrari, and G. Torelli, “Hepatitis C virus
genotype distribution in B-cell non-Hodgkin lymphoma,”
Annals of Internal Medicine, vol. 128, no. 7, p. 602, 1998.
[34] H. A. Torres, M. Nevah-Rubin, B. J. Barnett et al., “Variation
of hepatitis C virus genotype distribution between geograph-
ically related patients: a retrospective multicenter,” Journal
of Clinical Oncology, vol. 29, supplement, ASCO Meeting
Abstract no. 8052, 2011.
[35] O. Hermine, F. Lefrère, J. P. Bronowicki et al., “Regression of
splenic lymphoma with villous lymphocytes after treatment of
hepatitis C virus infection,” New England Journal of Medicine,
vol. 347, no. 2, pp. 89–94, 2002.
[36] D. Vallisa, P. Bernuzzi, L. Arcaini et al., “Role of anti-hepatitis
C virus (HCV) treatment in HCV-related, low-grade, B-cell,
non-Hodgkin’s lymphoma: a multicenter Italian experience,”
Journal of Clinical Oncology, vol. 23, no. 3, pp. 468–473, 2005.
[37] L. Arcaini, D. Vallisa, M. Merli et al., “Hematological response
to antiviral therapy in 94 patients with indolent B-cell
lymphomas associated with hepatitis C virus infection: a study
of the Fondazione Italiana Linfomi (FIL),” Annals of Oncology,
vol. 22, Lugano Meeting Abstract no. 138, pp. 128–129, 2011.
[38] J. P. Gisbert, L. Garcı́a-Buey, J. M. Pajares, and R. Moreno-
Otero, “Systematic review: regression of lymphoproliferative
disorders after treatment for hepatitis C infection,” Alimentary
Pharmacology and Therapeutics, vol. 21, no. 6, pp. 653–662,
2005.
[39] V. La Mura, A. D. Renzo, F. Perna et al., “Antiviral therapy
after complete response to chemotherapy could be efficacious
in HCV-positive non-Hodgkin’s lymphoma,” Journal of Hepa-
tology, vol. 49, no. 4, pp. 557–563, 2008.
[40] Y. Kawamura, K. Ikeda, Y. Arase et al., “Viral Elimination
Reduces Incidence of Malignant Lymphoma in Patients with
Hepatitis C,” American Journal of Medicine, vol. 120, no. 12,
pp. 1034–1041, 2007.
[41] F. Poordad, J. McCone, B. R. Bacon et al., “Boceprevir for
untreated chronic HCV genotype 1 infection,” New England
Journal of Medicine, vol. 364, no. 13, pp. 1195–1206, 2011.
[42] I. M. Jacobson, J. G. McHutchison, G. Dusheiko et al.,
“Telaprevir for previously untreated chronic hepatitis C virus
infection,” New England Journal of Medicine, vol. 364, no. 25,
pp. 2405–2416, 2011.
[43] J. Pawlotsky, “The results of phase III clinical trials with
telaprevir and boceprevir presented at the liver meeting 2010: a
new standard of care for hepatitis C virus genotype 1 infection,
but with issues still pending,” Gastroenterology, vol. 140, no. 3,
pp. 746–754, 2011.
[44] A. Nooka, P. J. Shenoy, R. Sinha et al., “Hepatitis C reactivation
in patients who have diffuse large B-cell lymphoma treated
with rituximab: a case report and review of literature,” Clinical
Lymphoma Myeloma and Leukemia, vol. 11, pp. 379–384,
2011.
[45] M. Merli, M. Spina, S. Luminari et al., “Prognostic models
to predict survival in indolent and aggressive non-Hodgkin’s
lymphomas associated with hepatitis C virus infection: a
multicenter Italian study on 1, 043 patients,” in Proceedings of
the 52nd American Society of Hematology Annual Meeting, vol.
116, no. 2821, 2010.
[46] S. Vento, F. Cainelli, F. Mirandola et al., “Fulminant hepatitis
on withdrawal of chemotherapy in carriers of hepatitis C
virus,” Lancet, vol. 347, no. 8994, pp. 92–93, 1996.
[47] M. C. Cox, M. A. Aloe-Spiriti, and E. Cavalieri, “HCV infec-
tion, B-cell non-Hodgkin’s lymphoma and immunochemo-
therapy: evidence and open questions,” World Journal of
Gastrointestinal Oncology, vol. 15, pp. 46–53, 2012.
[48] D. A. Landau, D. Saadoun, L. H. Calabrese, and P. Cacoub,
“The pathophysiology of HCV induced B-cell clonal disor-
ders,” Autoimmunity Reviews, vol. 6, no. 8, pp. 581–587, 2007.
[49] A. Stathis, F. Bertoni, and E. Zucca, “Treatment of gastric
marginal zone lymphoma of MALT type,” Expert Opinion on
Pharmacotherapy, vol. 11, no. 13, pp. 2141–2152, 2010.
[50] A. Zullo, C. Hassan, A. Andriani et al., “Treatment of low-
grade gastric MALT-lymphoma unresponsive to Helicobacter
pylori therapy: a pooled-data analysis,” Medical Oncology, vol.
27, no. 2, pp. 291–295, 2010.
[51] V. De Re, S. De Vita, A. Marzotto et al., “Pre-malignant and
malignant lymphoproliferations in an HCV-infected type II
mixed cryoglobulinemic patient are sequential phases of an
antigen-driven pathological process,” International Journal of
Cancer, vol. 87, pp. 211–216, 2000.
[52] P. D. Gorevic and B. Frangione, “Mixed cryoglobulinemia
cross-reactive idiotypes: implications for the relationship of
MC to rheumatic and lymphoproliferative diseases,” Seminars
in Hematology, vol. 28, no. 2, pp. 79–94, 1991.
[53] R. Marasca, P. Vaccari, M. Luppi et al., “Immunoglobulin gene
mutations and frequent use of VH1-69 and VH4-34 segments
in hepatitis C virus-positive and hepatitis C virus-negative
8 Clinical and Developmental Immunology
nodal marginal zone B-cell lymphoma,” American Journal of
Pathology, vol. 159, no. 1, pp. 253–261, 2001.
[54] T. Allander, K. Drakenberg, A. Beyene et al., “Recombinant
human monoclonal antibodies against different conforma-
tional epitopes of the E2 envelope glycoprotein of hepatitis C
virus that inhibit its interaction with CD81,” Journal of General
Virology, vol. 81, no. 10, pp. 2451–2459, 2000.
[55] C. H. Chan, K. G. Hadlock, S. K. H. Foung, and S. Levy, “VH1-
69 gene is preferentially used by hepatitis C virus-associated B
cell lymphomas and by normal B cells responding to the E2
viral antigen,” Blood, vol. 97, no. 4, pp. 1023–1026, 2001.
[56] V. De Re, S. De Vita, A. Marzotto et al., “Sequence analysis
of the immunoglobulin antigen receptor of hepatitis C virus
Associated non-Hodgkin lymphomas suggests that the malig-
nant cells are derived from the rheumatoid factorn Producing
cells that occur mainly in type II cryoglobulinemia,” Blood, vol.
96, no. 10, pp. 3578–3584, 2000.
[57] R. Lesniewski, G. Okasinski, R. Carrick et al., “Antibody to
hepatitis C virus second envelope (HCV-E2) glycoprotein: a
new marker of HCV infection closely associated with viremia,”
Journal of Medical Virology, vol. 45, no. 4, pp. 415–422, 1995.
[58] E. R. Quinn, C. H. Chan, K. G. Hadlock, S. K. H. Foung, M.
Flint, and S. Levy, “The B-cell receptor of a hepatitis C virus
(HCV)-associated non-Hodgkin lymphoma binds the viral
E2 envelope protein, implicating HCV in lymphomagenesis,”
Blood, vol. 98, no. 13, pp. 3745–3749, 2001.
[59] S. Hermouet, I. Corre, M. Gassin, E. Bigot-Corbel, C. A.
Sutton, and J. W. Casey, “Hepatitis C virus, human herpesvirus
8, and the development of plasma-cell leukemia,” New England
Journal of Medicine, vol. 348, no. 2, pp. 178–179, 2003.
[60] A. K. Matsumoto, D. R. Martin, R. H. Carter, L. B. Klickstein,
J. M. Ahearn, and D. T. Fearon, “Functional dissection of
the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes,”
Journal of Experimental Medicine, vol. 178, no. 4, pp. 1407–
1417, 1993.
[61] R. H. Carter and D. T. Fearon, “CD19: lowering the threshold
for antigen receptor stimulation of B lymphocytes,” Science,
vol. 256, no. 5053, pp. 105–107, 1992.
[62] D. Rosa, G. Saletti, E. De Gregorio et al., “Activation of
naı̈ve B lymphocytes via CD81, a pathogenetic mechanism
for hepatitis C virus-associated B lymphocyte disorders,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 102, no. 51, pp. 18544–18549, 2005.
[63] A. Wack, E. Soldaini, C. Tseng -TK, S. Nuti, G. R. Klimpel,
and S. Abrignani, “Binding of the hepatitis C virus envelope
protein E2 to CD81 provides a costimulatory signal for human
T cells,” European Journal of Immunology, vol. 31, pp. 166–175,
2001.
[64] M. Poetsch, K. Weber-Matthiesen, H. J. Plendl, W. Grote, and
B. Schlegelberger, “Detection of the t(14:18) chromosomal
translocation by interphase cytogenetics with Yeast-artificial-
chromosome probes in follicular lymphoma and nonneoplas-
tic lymphoproliferation,” Journal of Clinical Oncology, vol. 14,
no. 3, pp. 963–969, 1996.
[65] Z. Chen, Y. Zhu, Y. Ren et al., “Hepatitis C virus protects
human B lymphocytes from fas-mediated apoptosis via E2-
CD81 engagement,” PLoS One, vol. 6, no. 4, Article ID e18933,
2011.
[66] K. Machida, K. T. H. Cheng, N. Pavio, V. M. H. Sung,
and M. M. C. Lai, “Hepatitis C virus E2-CD81 interaction
induces hypermutation of the immunoglobulin gene in B
cells,” Journal of Virology, vol. 79, no. 13, pp. 8079–8089, 2005.
[67] M. Ito, H. Kusunoki, and K. Mochida, “HCV infection and
B-cell lymphomagenesis,” Advances in Hematology , vol. 2011,
Article ID 835314, 8 pages, 2011.
[68] M. Houghton, A. Weiner, J. Han, G. Kuo, and Q. L. Choo,
“Molecular biology of the hepatitis C viruses: implications
for diagnosis, development and control of viral disease,”
Hepatology, vol. 14, no. 2, pp. 381–388, 1991.
[69] J. H. Han, V. Shyamala, K. H. Richman et al., “Character-
ization of the terminal regions of hepatitis C viral RNA:
identification of conserved sequences in the 5’ untranslated
region and poly(A) tails at the 3’ end,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 88, no. 5, pp. 1711–1715, 1991.
[70] A. L. Zignego, D. Macchia, M. Monti et al., “Infection of
peripheral mononuclear blood cells by hepatitis C virus,”
Journal of Hepatology, vol. 15, no. 3, pp. 382–386, 1992.
[71] C. Ferri, M. Monti, L. La Civita et al., “Infection of peripheral
blood mononuclear cells by hepatitis C virus in mixed
cryoglobulinemia,” Blood, vol. 82, no. 12, pp. 3701–3704, 1993.
[72] M. Inokuchi, T. Ito, M. Uchikoshi et al., “Infection of B cells
with hepatitis C virus for the development of lymphoprolifer-
ative disorders in patients with chronic hepatitis C,” Journal of
Medical Virology, vol. 81, no. 4, pp. 619–627, 2009.
[73] G. Morsica, G. Tambussi, G. Sitia et al., “Replication of
hepatitis C virus in B lymphocytes (CD19+),” Blood, vol. 94,
no. 3, pp. 1138–1139, 1999.
[74] D. Sansonno, A. R. Iacobelli, V. Cornacchiulo, G. Iodice, and
F. Dammacco, “Detection of hepatitis C virus (HCV) proteins
by immunofluorescence and HCV RNA genomic sequences
by non-isotopic in situ hybridization in bone marrow and
peripheral blood mononuclear cells of chronically HCV-
infected patients,” Clinical and Experimental Immunology, vol.
103, no. 3, pp. 414–421, 1996.
[75] R. E. Lanford, D. Chavez, F. V. Chisari, and C. Sureau, “Lack
of detection of negative-strand hepatitis C virus RNA in
peripheral blood mononuclear cells and other extrahepatic
tissues by the highly strand- specific rTth reverse transcriptase
PCR,” Journal of Virology, vol. 69, no. 12, pp. 8079–8083, 1995.
[76] M. Willems, H. Moshage, and Sing Hiem Yap, “PCR and
detection of negative HCV RNA strands,” Hepatology, vol. 17,
no. 3, p. 526, 1993.
[77] S. Marukian, C. T. Jones, L. Andrus et al., “Cell culture-
produced hepatitis C virus does not infect peripheral blood
mononuclear cells,” Hepatology, vol. 48, no. 6, pp. 1843–1850,
2008.
[78] Z. Stamataki, C. Shannon-Lowe, J. Shaw et al., “Hepatitis
C virus association with peripheral blood B lymphocytes
potentiates viral infection of liver-derived hepatoma cells,”
Blood, vol. 113, no. 3, pp. 585–593, 2009.
[79] M. P. Curry, L. Golden-Mason, D. G. Doherty et al., “Expan-
sion of innate CD5pos B cells expressing high levels of CD81
in hepatitis C virus infected liver,” Journal of Hepatology, vol.
38, no. 5, pp. 642–650, 2003.
[80] Y. Sugawara, M. Makuuchi, N. Kato, K. Shimotohno, and
K. Takada, “Enhancement of hepatitis C virus replication
by Epstein-Barr virus-encoded nuclear antigen 1,” EMBO
Journal, vol. 18, no. 20, pp. 5755–5760, 1999.
[81] A. M. Levine, S. Shimodaira, and M. M. C. Lai, “Treatment
of HCV-related mantle-cell lymphoma with ribavirin and
pegylated interferon alfa,” New England Journal of Medicine,
vol. 349, no. 21, pp. 2078–2079, 2003.
Clinical and Developmental Immunology 9
[82] M. Ohsawa, Y. Tomita, M. Hashimoto, H. Kanno, and K.
Aozasa, “Hepatitis C viral genome in a subset of primary
hepatic lymphomas,” Modern Pathology, vol. 11, no. 5, pp.
471–478, 1998.
[83] M. H. V. Sung, S. Shimodaira, A. L. Doughty et al., “Establish-
ment of B-cell lymphoma cell lines persistently infected with
hepatitis C virus in vivo and in vitro: the apoptotic effects of
virus infection,” Journal of Virology, vol. 77, no. 3, pp. 2134–
2146, 2003.
[84] C. Caussin-Schwemling, C. Schmitt, and F. Stoll-Keller,
“Study of the infection of human blood derived mono-
cyte/macrophages with hepatitis C virus in vitro,” Journal of
Medical Virology, vol. 65, pp. 14–22, 2001.
[85] J. Greeve, A. Philipsen, K. Krause et al., “Expression of
activation-induced cytidine deaminase in human B-cell non-
Hodgkin lymphomas,” Blood, vol. 101, no. 9, pp. 3574–3580,
2003.
[86] M. C. Navas, A. Fuchs, E. Schvoerer, A. Bohbot, A. M.
Aubertin, and F. Stoll-Keller, “Dendritic cell susceptibility to
hepatitis C virus genotype 1 infection,” Journal of Medical
Virology, vol. 67, no. 2, pp. 152–161, 2002.
[87] K. Tsukiyama-Kohara, S. Sekiguchi, Y. Kasama, N. E. Salem,
K. Machida, and M. Kohara, “Hepatitis C virus-related
lymphomagenesis in a mouse model,” ISRN Hematology, vol.
2011, Article ID 167501, 8 pages, 2011.
[88] M. Ito, K. Murakami, T. Suzuki et al., “Enhanced expression
of lymphomagenesis-related genes in peripheral blood B cells
of chronic hepatitis C patients,” Clinical Immunology, vol. 135,
no. 3, pp. 459–465, 2010.
[89] K. Machida, K. T. N. Cheng, V. M. H. Sung et al., “Hepatitis
C virus induces a mutator phenotype: enhanced mutations
of immunoglobulin and protooncogenes,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 101, no. 12, pp. 4262–4267, 2004.
[90] Y. Kitay-Cohen, A. Amiel, N. Hilzenrat et al., “Bcl-2 rear-
rangement in patients with chronic hepatitis C associated with
essential mixed cryoglobulinemia type II,” Blood, vol. 96, no.
8, pp. 2910–2912, 2000.
[91] A. L. Zignego, C. Ferri, F. Giannelli et al., “Prevalence of bcl-2
rearrangement in patients with hepatitis C virus-related mixed
cryoglobulinemia with or without B-cell lymphomas,” Annals
of Internal Medicine, vol. 137, no. 7, pp. 571–580, 2002.
[92] S. Swaminathan, “Molecular biology of Epstein-Barr virus
and Kaposi’s sarcoma-associated herpesvirus,” Seminars in
Hematology, vol. 40, no. 2, pp. 107–115, 2003.
















































Oxidative Medicine and 
Cellular Longevity
ISRN 
Addiction
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
International Journal of
Endocrinology
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2013
ISRN 
Anesthesiology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
BioMed Research 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Hindawi Publishing Corporation
http://www.hindawi.com
Oncology
Journal of
Volume 2013
Ophthalmology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
Obesity
Journal of
ISRN 
Allergy
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
PPAR
Re sea rch
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2013
